Dicerna's RNAi drug shows 'inconsistent' results in rare kidney disease, tanking shares despite trial win

Dicerna’s nedosiran, an RNAi therapeutic being tested in patients with a rare kidney disease known as primary hyperoxaluria, hit the primary endpoint for a pivotal study, the company said Thursday, but shares plummeted after efficacy data in a sought-after patient subpopulation showed no benefit over placebo.